Pernix Therapeutics Holdings Inc (NYSE:PTX) reported on Tuesday that it is purchasing Somaxon Pharmaceuticals, Inc (NASDAQ:SOMX) in a stock-for-stock agreement, worth at $25 million.
The Woodlands, Texas based Pernix anticipates to benefit from Somaxon’s insomnia drug Silenor in the purchase, which is subject to the endorsement of the San Diego, California based Somaxon’s shareholders.
The company reported that the number of shares that Somaxon shareholders will get upon the completion of merger is based on the median price of Pernix’s stock over the 30-day period finishing on the day before the ending of the proposed pact, according to the terms of the deal but subject to few limitations.
Its competitors include Pfizer Inc (NYSE:PFE) that increased +0.87% to $25.63 with the total traded volume of 1.92 million shares and Johnson & Johnson (NYSE:JNJ) that increased +0.89% to $71.24 with the total traded volume of 1.50 million shares.
Other Healthcare stocks with bullish trend include CARDIOME PHARMA CORP (NASDAQ:CRME) up +49.88% to $0.375, Depomed Inc (NASDAQ:DEPO) up +1.22% to $5.89 and Allergan, Inc (NYSE:AGN) up +1.22% to $93.14, whereas with bearish trend include Amarin Corporation plc (ADR) (NASDAQ:AMRN) down -2.03% to $9.15, Dynavax Technologies Corporation (NASDAQ:DVAX) no change for the day to $2.55 and Alexza Pharmaceuticals, Inc (NASDAQ:ALXA) down -0.52% to $5.25.
Pernix Therapeutics Holdings Inc (NYSEAMEX:PTX) stock in current session held volume of 3,541.00 shares as compare to its average volume of 16,842.00 shares. The stock after opening at $7.98 hit high price of $7.98 and then trading at $7.97 by scoring +0.50%.
As the revenue measures PTX generated revenue of 64.52 million in the following twelve months income of $3.87 million. The Company showed a positive 5.99% in the net profit margin and in addition to in its operating margin which remained 9.12%.
The stock showed weekly upbeat performance of +8.04% which was maintained for the month at +8.33%. Likewise the negative performance for the quarter was recorded as +13.61% and for the year was -11.89% while the YTD performance remained at -14.36%.
The PTX past twelve months price to sales ratio was 3.58 and price to cash ratio remained 6.23. As far as the returns are concern, the PTX return on equity was recorded as 6.31% and increased 5.69% return on investment while its return on asset stayed at 4.08%.
DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK Q